Research graph
References from The Tumour-Suppressive Role of Myosin Heavy Chain 9 (MYH9) in Oral Squamous Cell Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Current trends of targeted therapy for oral squamous cell carcinoma
10.1007/s00432-022-04028-8 · 2022 · External reference
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis
10.1091/mbc.e10-04-0293 · 2010 · External reference
In vivo studies on nonmuscle myosin II expression and function in heart development
10.2741/3942 · 2012 · External reference
Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly
10.1038/79069 · 2000 · External reference
Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome)
10.1182/blood.v97.4.1147 · 2001 · External reference
Myosin heavy chain 9: oncogene or tumor suppressor gene?
10.12659/msm.912320 · 2019 · External reference
Clinicopathological significance of NMIIA overexpression in human gastric cancer
10.3390/ijms131115291 · 2012 · External reference
MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis
10.1002/cbin.11894 · 2022 · External reference
Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review
10.1186/s12964-024-01781-w · 2024 · External reference
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas
10.1126/science.1248627 · 2014 · External reference
Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma
2015 · External reference
MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment
10.1007/s12032-020-01413-6 · 2020 · External reference
p22phox confers resistance to cisplatin, by blocking its entry into the nucleus
10.18632/oncotarget.2893 · 2015 · External reference
Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: implications of alternative treatment strategies
10.1002/hed.24803 · 2017 · External reference
Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma
10.1016/j.oraloncology.2013.01.003 · 2013 · External reference
Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness, drug resistance and metastasis via regulating RABIF/MMP signaling in triple negative breast cancer
10.3390/cells10102524 · 2021 · External reference
EZH2-mediated downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells
10.1158/0008-5472.can-20-0458 · 2020 · External reference
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
10.1016/j.drup.2021.100770 · 2021 · External reference
Regulating tumor suppressor genes: post-translational modifications
10.1038/s41392-020-0196-9 · 2020 · External reference
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents
10.1038/s41392-020-00430-1 · 2021 · External reference
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9
10.1016/j.omto.2022.08.003 · 2022 · External reference
A key protein involved in tumor progression and virus-related diseases
10.1016/j.biopha.2023.116118 · 2024 · External reference
Role of myosin heavy chain 9 in gastrointestinal tumorigenesis: a comprehensive review
10.4251/wjgo.v17.i6.106617 · 2025 · External reference
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer
10.18632/oncotarget.14967 · 2017 · External reference
MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway
10.1038/s41598-025-87151-z · 2025 · External reference
NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway
10.18632/aging.204377 · 2022 · External reference
MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling
10.1038/s41420-021-00681-z · 2021 · External reference
LncRNA AFAP1-AS1 promotes oral squamous cell carcinoma development by ubiquitin-mediated proteolysis
10.1016/j.identj.2024.04.024 · 2024 · External reference
The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma
10.1038/s41392-024-01963-5 · 2024 · External reference
Targeting the SPC25/RIOK1/MYH9 axis to overcome tumor stemness and platinum resistance in epithelial ovarian cancer
2024 · External reference
Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/NOTCH/ DDR axis in pancreatic ductal adenocarcinoma
10.1038/s41419-024-07110-w · 2024 · External reference
Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway
10.1038/s41420-022-00933-6 · 2022 · External reference
ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK
10.1186/s13046-023-02904-w · 2023 · External reference
Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9
10.1038/s41392-019-0084-3 · 2019 · External reference
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma
10.1038/ng.3905 · 2017 · External reference
Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis
10.7150/thno.46001 · 2020 · External reference
TTK defines a high-risk oral squamous cell carcinoma subtype through dual mTORC1/NF-κB activation
10.1016/j.identj.2025.103945 · 2025 · External reference
Myosin II dynamics and cortical flow during contractile ring formation in Dictyostelium cells
10.1083/jcb.200011013 · 2001 · External reference
Evolution of polymer formation within the actin superfamily
10.1091/mbc.e15-11-0778 · 2017 · External reference
MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis
10.1002/cbin.11894 · ExternalCitation · doi-reference
Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: implications of alternative treatment strategies
10.1002/hed.24803 · ExternalCitation · doi-reference
Current trends of targeted therapy for oral squamous cell carcinoma
10.1007/s00432-022-04028-8 · ExternalCitation · doi-reference
MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment
10.1007/s12032-020-01413-6 · ExternalCitation · doi-reference
A key protein involved in tumor progression and virus-related diseases
10.1016/j.biopha.2023.116118 · ExternalCitation · doi-reference
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
10.1016/j.drup.2021.100770 · ExternalCitation · doi-reference
LncRNA AFAP1-AS1 promotes oral squamous cell carcinoma development by ubiquitin-mediated proteolysis
10.1016/j.identj.2024.04.024 · ExternalCitation · doi-reference
TTK defines a high-risk oral squamous cell carcinoma subtype through dual mTORC1/NF-κB activation
10.1016/j.identj.2025.103945 · ExternalCitation · doi-reference
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9
10.1016/j.omto.2022.08.003 · ExternalCitation · doi-reference
Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma
10.1016/j.oraloncology.2013.01.003 · ExternalCitation · doi-reference
Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly
10.1038/79069 · ExternalCitation · doi-reference
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma
10.1038/ng.3905 · ExternalCitation · doi-reference
Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9
10.1038/s41392-019-0084-3 · ExternalCitation · doi-reference
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents
10.1038/s41392-020-00430-1 · ExternalCitation · doi-reference
Regulating tumor suppressor genes: post-translational modifications
10.1038/s41392-020-0196-9 · ExternalCitation · doi-reference
The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma
10.1038/s41392-024-01963-5 · ExternalCitation · doi-reference
Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/NOTCH/ DDR axis in pancreatic ductal adenocarcinoma
10.1038/s41419-024-07110-w · ExternalCitation · doi-reference
MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling
10.1038/s41420-021-00681-z · ExternalCitation · doi-reference
Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway
10.1038/s41420-022-00933-6 · ExternalCitation · doi-reference
MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway
10.1038/s41598-025-87151-z · ExternalCitation · doi-reference
Myosin II dynamics and cortical flow during contractile ring formation in Dictyostelium cells
10.1083/jcb.200011013 · ExternalCitation · doi-reference
Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis
10.1091/mbc.e10-04-0293 · ExternalCitation · doi-reference
Evolution of polymer formation within the actin superfamily
10.1091/mbc.e15-11-0778 · ExternalCitation · doi-reference
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas
10.1126/science.1248627 · ExternalCitation · doi-reference
EZH2-mediated downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells
10.1158/0008-5472.can-20-0458 · ExternalCitation · doi-reference
Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome)
10.1182/blood.v97.4.1147 · ExternalCitation · doi-reference
Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review
10.1186/s12964-024-01781-w · ExternalCitation · doi-reference
ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK
10.1186/s13046-023-02904-w · ExternalCitation · doi-reference
Myosin heavy chain 9: oncogene or tumor suppressor gene?
10.12659/msm.912320 · ExternalCitation · doi-reference
NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway
10.18632/aging.204377 · ExternalCitation · doi-reference
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer
10.18632/oncotarget.14967 · ExternalCitation · doi-reference
p22phox confers resistance to cisplatin, by blocking its entry into the nucleus
10.18632/oncotarget.2893 · ExternalCitation · doi-reference
In vivo studies on nonmuscle myosin II expression and function in heart development
10.2741/3942 · ExternalCitation · doi-reference
Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness, drug resistance and metastasis via regulating RABIF/MMP signaling in triple negative breast cancer
10.3390/cells10102524 · ExternalCitation · doi-reference
Clinicopathological significance of NMIIA overexpression in human gastric cancer
10.3390/ijms131115291 · ExternalCitation · doi-reference
Role of myosin heavy chain 9 in gastrointestinal tumorigenesis: a comprehensive review
10.4251/wjgo.v17.i6.106617 · ExternalCitation · doi-reference
Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis
10.7150/thno.46001 · ExternalCitation · doi-reference
